Sermorelin and ipamorelin are often mentioned together because both raise growth hormone, but they belong to different peptide classes and reach that effect by different routes. Sermorelin is a GHRH analog; ipamorelin is a selective growth-hormone secretagogue that works through the ghrelin receptor. This comparison sticks to what the sourced evidence supports.
Reviewed for accuracy · Last reviewed July 7, 2026The clearest difference is mechanism. Sermorelin is a GHRH analog that stimulates the pituitary's GHRH receptor, while ipamorelin acts on the separate ghrelin receptor. The two are sometimes discussed as complementary rather than interchangeable, because a GHRH analog and a GHRP-class peptide act on different pathways.
On evidence, sermorelin has the deeper human record, from its historical approved use as Geref in pediatric growth-hormone deficiency and diagnostic testing. Ipamorelin's defining characterization is preclinical, and its main human trial (for postoperative ileus) did not meet its primary endpoint, so its evidence base is thinner and it has never been approved.
A frequently cited practical point for ipamorelin is selectivity: unlike some older GHRP peptides, it was reported not to meaningfully raise ACTH or cortisol. That is a mechanistic finding, not a statement that it is safe or effective for body-composition or anti-aging use, none of which is approved. Which, if either, is appropriate is a medical decision.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting any compound.